REAL-WORLD DATA ON THE EFFICACY AND SAFETY OF PAZOPANIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA AT K HOSPITAL
.
Abstract
Background: Pazopanib is an effective first-line treatment for advanced renal cell carcinoma (RCC), but its efficacy and safety in the Vietnamese population are not well-documented. This study evaluates the outcomes and adverse effects of pazopanib at K Hospital, with a focus on the impact of initial dosing.
Methods: A retrospective and prospective study of 60 patients with advanced RCC treated with pazopanib between January 2018 and July 2024. The initial doses were 200mg, 400mg, 600mg, or 800mg. Primary endpoints were overall response rate (ORR) and disease control rate (DCR), with secondary endpoints including progression-free survival (PFS), overall survival (OS), and adverse events.
Results: The ORR was 45%, with 3.3% achieving complete response and 41.7% partial response. Median PFS was 13.1 months, and median OS was 21.5 months. The initial dose of pazopanib did not significantly affect OS (25.5 months for 800mg vs. 20.5 months for lower doses, p=0.945). Common adverse effects included elevated liver enzymes and fatigue.
Conclusions: Pazopanib is effective and well-tolerated in the Vietnamese population, with no significant impact of initial dosing on overall survival. Dose adjustments based on tolerability may be beneficial. Further research with larger samples and longer follow-up is needed to confirm these findings.
.
Keywords
Renal cell carcinoma, Pazopanib, advanced stage
- Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/today, accessed.
- Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev. 2008;34(3):193-205. doi:10.1016/j.ctrv.2007.12.001
- NCCN guidelines, Kidney cancer, version 2.2024. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.
- Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-731. doi:10.1056/NEJMoa1303989
- Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(14):1412-1418. doi:10.1200/JCO.2013.50.8267
- Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116-1127. doi:10.1056/NEJMoa1816714
- Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277-1290. doi:10.1056/NEJMoa1712126
